Press releases

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN, SOUTH AFRICA OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN, SOUTH AFRICA OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL

Stockholm - March 8, 2018 - Oncopeptides AB (Nasdaq Stockholm; ONCO) announced today that the Japanese Patent Office (JPO) recently issued a notice that they will grant an additional Japanese patent to Oncoeptides AB

Stockholm, Sweden – Oncopeptides AB (Nasdaq Stockholm; ONCO) today announced the Year-end report 2017

Stockholm – December 10th, 2017 - Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that the first survival data were presented at the annual meeting of the American Society of Hematology from the phase II-study O-12-M1 in late-stage patients with Relapsed Refractory Multiple Myeloma (RRMM)

Stockholm – December 9th, 2017 - Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that interim data was presented at the American Society of Hematology from the ongoing phase II study HORIZON, treating late-stage patients with Relapsed Refractory Multiple Myeloma (RRMM) that are also refractory to pomalidomide and/or daratumumab

Stockholm, Sweden – Oncopeptides AB (Nasdaq Stockholm; ONCO) today announced the third quarter 2017 report. “The data from our study, O-12-M1, provides us with an increased degree of comfort regarding a positive clinical outcome in our pivotal study OCEAN”

Stockholm – November 7, 2017 - Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that they will attend Jefferies annual Healthcare Conference in London on November 16th

Stockholm – November 1, 2017 - Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that they will present results from two clinical studies at ASH in Atlanta, US: Final data from the phase II study called O-12-M1 and interim data from the ongoing phase II study called HORIZON. Both studies target late-stage patients with Relapsed Refractory Multiple Myeloma (RRMM)

Stockholm - October 17, 2017 - According to the principles for the appointment of the Nomination Committee in Oncopeptides AB adopted at the annual general meeting held on 18 May 2017, the Nomination Committee for the annual general meeting 2018 shall be composed of members appointed by the three largest